China’s Central Government Introduces Major Policy Incentives and Restraints to the MedTech Industry

Published date20 August 2019
Subject MatterChina,Competition,Hospitals,Research and Development,Pharmaceutical Industry,Biotechnology,Supply Chain,Medical Devices,Multinationals,Life Sciences,Enforcement Actions,Federal Pilot Programs
AuthorKatherine Wang
Law FirmRopes & Gray LLP

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT